Cover Image

The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images

Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there a...

Full description

Saved in:
Bibliographic Details
Main Authors: Suppiah, Subapriya, Didier, Mellanie Anne, Vinjamuri, Sobhan
Format: Article
Language:English
Published: MDPI 2019
Online Access:http://psasir.upm.edu.my/id/eprint/82617/1/The%20who.pdf
http://psasir.upm.edu.my/id/eprint/82617/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.upm.eprints.82617
record_format eprints
spelling my.upm.eprints.826172020-10-17T21:41:19Z http://psasir.upm.edu.my/id/eprint/82617/ The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images Suppiah, Subapriya Didier, Mellanie Anne Vinjamuri, Sobhan Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there are three FDA approved amyloid radiotracers used in clinical practice. This review aims to take the readers through the array of various indications for performing amyloid PET imaging in the management of AD, particularly using 18F-labelled radiopharmaceuticals. We elaborate on PET amyloid scan interpretation techniques, their limitations and potential improved specificity provided by interpretation done in tandem with genetic data such as apolipiprotein E (APO) 4 carrier status in sporadic cases and molecular information (e.g., cerebral spinal fluid (CSF) amyloid levels). We also describe the quantification methods such as the standard uptake value ratio (SUVr) method that utilizes various cutoff points for improved accuracy of diagnosing AD, such as a threshold of 1.122 (area under the curve 0.894), which has a sensitivity of 92.3% and specificity of 90.5%, whereas the cutoff points may be higher in APOE ε4 carriers (1.489) compared to non-carriers (1.313). Additionally, recommendations for future developments in this field are also provided. MDPI 2019-06 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/82617/1/The%20who.pdf Suppiah, Subapriya and Didier, Mellanie Anne and Vinjamuri, Sobhan (2019) The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images. Diagnostics, 9 (2). ISSN 2075-4418 10.3390/diagnostics9020065
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
language English
description Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there are three FDA approved amyloid radiotracers used in clinical practice. This review aims to take the readers through the array of various indications for performing amyloid PET imaging in the management of AD, particularly using 18F-labelled radiopharmaceuticals. We elaborate on PET amyloid scan interpretation techniques, their limitations and potential improved specificity provided by interpretation done in tandem with genetic data such as apolipiprotein E (APO) 4 carrier status in sporadic cases and molecular information (e.g., cerebral spinal fluid (CSF) amyloid levels). We also describe the quantification methods such as the standard uptake value ratio (SUVr) method that utilizes various cutoff points for improved accuracy of diagnosing AD, such as a threshold of 1.122 (area under the curve 0.894), which has a sensitivity of 92.3% and specificity of 90.5%, whereas the cutoff points may be higher in APOE ε4 carriers (1.489) compared to non-carriers (1.313). Additionally, recommendations for future developments in this field are also provided.
format Article
author Suppiah, Subapriya
Didier, Mellanie Anne
Vinjamuri, Sobhan
spellingShingle Suppiah, Subapriya
Didier, Mellanie Anne
Vinjamuri, Sobhan
The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
author_facet Suppiah, Subapriya
Didier, Mellanie Anne
Vinjamuri, Sobhan
author_sort Suppiah, Subapriya
title The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
title_short The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
title_full The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
title_fullStr The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
title_full_unstemmed The who, when, why, and how of PET Amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
title_sort who, when, why, and how of pet amyloid imaging in management of alzheimer’s disease-review of literature and interesting images
publisher MDPI
publishDate 2019
url http://psasir.upm.edu.my/id/eprint/82617/1/The%20who.pdf
http://psasir.upm.edu.my/id/eprint/82617/
_version_ 1681490859622662144
score 13.211869

Similar Items